| Pharmaceutical Information |
| Drug Name |
Basiliximab |
| Drug ID |
BADD_D00214 |
| Description |
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha. |
| Indications and Usage |
For prophylactic treatment of kidney transplant rejection |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AC02 |
| DrugBank ID |
DB00074
|
| KEGG ID |
D03058
|
| MeSH ID |
D000077552
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D06SBB
|
| NDC Product Code |
0078-0331; 0078-0393 |
| UNII |
9927MT646M
|
| Synonyms |
Basiliximab | Simulect | CHI 621 | SDZ CHI 621 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
179045-86-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
